SYFff61a36364bf4f23b2c7c9960b95a91fRegistry ID: 2023-509431-29-00|RecruitingPhase 2
Loading search results
interventional
N/A
1 country
1
To study whether the administration of Risedronate 10 mg/day in patients with dilated cardiomyopathy due to K210 deletion mutation in the Troponin T gene is associated with: A change in left ventricular function, measured by Echocardiogram
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 3, 2024
Actual (reported)Change in LVEF, measured by echocardiography, at 6 months.
Improvement in functional capacity, measured in the stress test with oxygen consumption, at 6 months.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Actonel 5 mg comprimidos recubiertos con película
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Actonel 5 mg comprimidos recubiertos con película
Named ingredient: Risedronate Sodium
View registry recordUniversity Clinical Hospital Virgen De La Arrixaca
Murcia, 30120, Spain
María Muñoz García
First Submitted
June 3, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
Contact the study team to confirm eligibility.